[April 21, 2016]

Metastatic Adenocarcinoma of The Pancreas Pipeline Review, H1 2016 - Research and Markets

Research and Markets has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Metastatic Adenocarcinoma of he Pancreas Overview
3. Therapeutics Development
4. Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
5. Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
6. Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
7. Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
8. Metastatic Adenocarcinoma of The Pancreas Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
13. Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
14. Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development

• AbbVie Inc.
• Aduro BioTech, Inc.
• Array BioPharma Inc.
• Axcentua Pharmaceuticals AB
• Berg LLC
• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• CTI (News - Alert) BioPharma Corp.
• CytRx Corporation
• Eleison Pharmaceuticals LLC
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• Incyte Corporation
• Merrimack Pharmaceuticals, Inc.
• NewLink Genetics Corporation
• Novartis AG
• Oncolytics Biotech Inc.
• Pfizer Inc.
• Phoenix Biotechnology, Inc.
• Plexxikon Inc.
• Sanofi
• Targovax AS

View source version on businesswire.com: http://www.businesswire.com/news/home/20160421005801/en/

[ Back To TMCnet.com's Homepage ]